| Primary information |
|---|
| OV_ID | OV_423 |
| Virus Name | Adenovirus |
| Strain | CRAd-IL24 (Ad5/3Δ24cmvIL24) |
| Virus type | DNA |
| Virus family | Adenoviridae |
| Modification in virus genome | Viral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). |
| Virus alone | Yes |
| Virus in combination iwth drug/radiation | No |
| Immune gene induction in virus genome | IL-24 gene incorporated in place of the deleted E3B region |
| Source of cell line | ATCC |
| Origin of cell line | Human ovary cancer cell line |
| Cell line | SKOV3luc OvCa |
| Concentration of cell line | 3 |
| In-vitro toxicity | Toxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells |
| Assay | MTS-based Cell Proliferation Assay (Promega) |
| In-vitro virus concentration | 33 MOI |
| In-vitro result | 16% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) |
| Model organism | No |
| In-vivo virus concentration | No |
| In-vivo toxicity | NA |
| In-vivo result | No response |
| Mode of delivery | NA |
| Pathway induction | NA |
| Immunogenic effect | NA |
| Clinical trial | NA |
| PMID | 27349517 |